CTOs on the Move

YO1 Center

www.yo1center.com

 
YO1 Center is a destination well-being place which enhances health, agility and longevity and brings your state of mind to bliss and happiness. Built at the erstwhile Kutsher`s Resort in lush green surroundings that have two large lakes, it gives guests the opportunity to naturally revitalize their mind and body by employing the Eastern practices brought all the way from India, namely Naturopathy (or Nature Cure), Ayurveda, Yoga and Meditation, Physical Therapy, Acupuncture, Diet and Nutrition. YO1 (or Yauvan) in Sanskrit means Youth. It is the golden period in every human being`s life between teenage and adulthood. It highlights the ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.yo1center.com
  • 420 Anawana Lake Road
    Monticello, NY USA 12701
  • Phone: 845.796.0186

Executives

Name Title Contact Details

Similar Companies

El Paso Orthopaedic Surgery Group

El Paso Orthopaedic Surgery Group is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in El Paso, TX. To find more information about El Paso Orthopaedic Surgery Group, please visit www.eposg.com

Memphis Center for Independent Living

Memphis Center for Independent Living is a Memphis, TN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ReGenesis Health Care

Community health center with four locations in Spartanburg County and one in Cherokee County. We have a dental practice and a pharmacy.

W R C Personal Care Services

W R C Personal Care Services is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Brookville, PA. To find more information about W R C Personal Care Services, please visit www.wrc.org

Immune Pharmaceuticals

Immune Pharmaceuticals applies a personalized approach to treatment, developing novel, highly targeted antibody therapeutics to improve the lives of patients with inflammatory diseases and cancer. The Company’s lead product candidate, bertilimumab, is entering Phase II clinical studies for moderate-to-severe ulcerative colitis and bullous pemphigoid, with additional studies planned for Crohn’s disease and severe asthma. The Company is evaluating the use of its NanomAb® platform, a second generation antibody drug conjugate technology, with chemotherapeutics in order to enhance their safety and efficacy profiles by delivering the medicines directly to cancer cells. The Company’s growing oncology pipeline also includes proprietary antibodies and, clinical-stage small molecules that have been shown activity in a variety of solid tumors. Immune is headquartered in the U.S., with its primary research and development facilities in Israel.